Wuxi Biologics (cayman) Inc. · HKEX:2269
Wuxi Biologics (cayman) — WuXi Biologics — ESG Presentation (September 2025)
39 slides from Wuxi Biologics (cayman)'s sustainability presentation, September 2025
Slide 1: WuXi Biologics Green CRDMO White Paper
WuXi Biologics Green CRDMO White Paper September, 2025 https://www.wuxibiologics.com/sustainability
Slide 2: Contents
Contents Foreword 01 Executive Summary 02 End-to-End Biologics Green CRDMO 05 1 Green Research 09 2 Green Development 12 3 Green Manufacturing 17 4 Green Operations 21 5 Best Practices 30 Closing Remarks 35 Disclaimer Reference 36 This White Paper is published by WuXi Biologics as a contribution to
Slide 3: Foreword
Foreword At WuXi Biologics, we believe that long-term business success is inseparable from our responsibility to people, society and the planet. Unleashing the power of our unique CRDMO business model, technology strength and operational excellence, WuXi Biologics has been successfully executing our
Slide 4: Executive Summary
Executive Summary Global endeavor to proactively tackle climate change Green transition to be the inevitable path for sustainable business development ﹣ Paris Agreement: aims to keep the global average temperature rise well below 2°C above pre-industrial Global Collaboration levels and to pursue eff
Slide 5: Executive Summary
Executive Summary Global governments to promote public procurement strategies for the green transition Key policy tools in place for achieving a low-carbon economy Federal Acquisition Regulation (FAR) and Environmentally Preferable Purchasing (EPP) GB/T 41835-2022 Sustainable Procurement Guidance, C
Slide 6: End-to-End Biologics Green CRDMO Solution
End-to-End Biologics Green CRDMO Solution Actively establish climate change target matrix to lead the path of net-zero economic transformation Committed to join SBTi SBTi Near-Term Targets SBTi Long-Term Targets Committed to net- ﹥ Reduce absolute GHG emissions1 ﹥ Reduce absolute GHG emissions1 90%
Slide 7: End-to-End Biologics Green CRDMO Solution
End-to-End Biologics Green CRDMO Solution Align with United Nations Sustainable Development Goals Industry Leader with Outstanding ESG Performance Join International Sustainable Development Initiatives Trusted Partner to Enable Global Clients DJSI World Indices MSCI ESG Ratings AAA S&P Global ESG In
Slide 8: Selected in UNGC 20 Case Examples for 20 Years
Selected in UNGC 20 Case Examples for 20 Years “ WuXi Biologics Leading in Green Biologics Solutions for a Healthier Future Vision Every biologic can be made. Mission Accelerate and transform the discovery, development and manufacturing of biologics to enable our global partners and benefit patients
Slide 9: End-to-End Biologics Green CRDMO Solution
End-to-End Biologics Green CRDMO Solution Driven by green innovative technologies Full lifecycle of biologics research,development,manufacturing Leverage lean management and digitalization Green Research Green Development Green Manufacturing Green Operations WuXiUI™ - Ultra-Intensified Highly flexib
Slide 10: Green Research
= Green Research
Slide 11: Green Research
Green Research Target (Concept) From Concept Antibody Discovery to IND Integrated Discovery Services Lead Optimization & Characterization IND Filing Support WuXi Biologics Green CRDMO White Paper 09
Slide 12: Green Research: WuXiBody Bispecific Platform
Green Research Proprietary Bispecific Antibody Accelerate 6-18 months of R & D timeline Technology Platform WuXiBody™ Significantly reduce production costs Empower global partners to develop innovative antibodies Minimize natural resource & energy consumption It has strong compatibility, and – throu
Slide 13: Green Development
Green Development
Slide 14: Green Development
Green Development Cell Line Engineering Assay Development Process Development Drug Product Development Drug-Device Combination Product Development DS & DP Scale Up Cell Banking & Characterization Pilot Scale Manufacturing Viral Clearance Late-stage Dev & PC/PV IND & BLA Filing Support Mammalian Mono
Slide 15: Novel and Green Technology Platforms Driven by Innovation
Green Development Novel and Green Technology Platforms Driven by Innovation Proven, High-Yielding Cell Line Ultra-High Productivity Rapid, High-Quality Protein Development Platform Continuous Processing Platform Production Platform Integrated ADC Drug Research Ultra-Intensified High-Concentration Pr
Slide 16: Ultra-High Productivity Continuous Processing Platform
Green Development Ultra-High Productivity Continuous Processing Platform Significantly reduce resin usage • Excellent developability and stability Less demand for production building space • Ensure the highest quality • 5 to 20-fold higher productivity Lower carbon footprint in facilities • Downstre
Slide 17: Innovative Ultra-Intensified Fed-Batch Platform
Green Development Innovative Ultra-Intensified Fed-Batch Platform Minimize media use • 3-6-fold increase in productivity Reduce waste generation • Notable increase in drug substance output by up to 500% at a similar production scale Up to 60% LCA reduction • Improve manufacturing efficiency and agil
Slide 18: Green Manufacturing
Green Manufacturing
Slide 19: Core Competence for Biologics Manufacturing
Green Manufacturing Core Competence for Biologics Manufacturing High Efficiency Cost Effective Environmental Friendly Large-Scale ◼ Technology Innovation ◼ Lifecycle Product Carbon Footprint (PCF) ⚫ Cover drug substance and drug product ⚫ Highly flexible Single-Use Technology (SUT) ⚫ Cover PCF calcu
Slide 20: Flexible Manufacturing Service to Meet Market Demand
Green Manufacturing Flexible Manufacturing Service to Meet Market Demand SUT + Advanced Technology Platform Scale-out Strategy Scale-up Strategy Largest scale ⚫ Explore the application of a range of larger volume single use bioreactors for scaled-up 16,000 L per batch commercial manufacturing, from
Slide 21: Global Leader in Single-Use Technology
Green Manufacturing Global Leader in Single-Use Technology Environmental Friendly Single-Use Technology (SUT)1 Leading Biologics Green Manufacturing 70% 30% Lower construction capital investment Water saving Electricity consumption reduction Reduced cleaning cost expenditure Shorter construction cyc
Slide 22: Green Operations
WuxXi Biologics Global Solution Provider,
Slide 23: From Commitment to Action: Leading the Way in Climate Change
Green Operations From Commitment to Action: Leading the Way in Climate Change SBTi Long-Term Targets SBTi targets approved SBTi Near-Term Targets ﹥ Reduce absolute GHG emissions 1 90% by Committed to net-zero Embarking on the net-zero journey ﹥ Reduce absolute GHG emissions 1 58.8% by 2034 2050 from
Slide 24: Building a Holistic Landscape for Green Technology
Green Operations Innovation-Driven Green Biologics Revolution Building a Holistic Landscape Resources Savings Across Resources Savings Across for Green Technology Global Sites in 2024 Global Sites from 2022 to 2024 Building a Holistic Landscape Diverse Systems 14,356 39,909 Spanning key processes, s
Slide 25: Building a Holistic Landscape for Green Technology
Green Operations Building a Holistic Landscape for Green Technology Process System Liquid Chilling System 4 subsystems with 46 best practices 6 subsystems with 96 best practices Cleanroom Heating, Ventilation & Air Conditioning System 5 subsystems with 69 best practices 7 subsystems with 125 best pr
Slide 26: Analysis on Green Practices: Site-Level GHG Emissions
Green Operations Analysis on Green Practices: A Structural Perspective of Site-Level GHG Emissions ◼ While comprehensively implementing energy-saving measures across our global sites, strategic prioritization should be directed toward critical systems following the Pareto Principle. ◼ Focus on Criti
Slide 27: Distribution of Energy-saving Projects Across Systems
Green Operations High Distribution of Energy-saving Projects Across Systems from 2022 to 2024 ◼ Diverse Systems: 12 energy systems ◼ Spanning key processes, systems and equipment from biologics research, development to manufacturing HVAC System ◼ Systematically advance carbon reduction initiatives C
Slide 28: Diverse Scenarios: Key Energy-Saving Scenarios
Green Operations Diverse Scenarios 5 Key Energy-Saving Scenarios Functional Area Production Area Laboratories Warehouses Office Area Utility Area • Drug Substance • Cell Culture Process Development • Central Weighing • Ambient Storage • Office & Meeting Rooms • Substation • Drug Product • Downstream
Slide 29: Distribution of Carbon Reduction by Main Energy Types
Green Operations Distribution of Carbon Reduction by Main Energy Types ◼ Diverse Energies: Electricity, Steam, Natural Gas from 2022 to 2024 ◼ Achieving operational synergy and substantial 2022 annual cost reductions 2023 2024 • Minimize dependence on environmental resources Carbon Reduction（tCO2e）
Slide 30: Diverse Technologies: Green Operations
Green Operations ◼ Diverse Technologies: 25 Categories ◼ Implement green technologies throughout the lifecycle to maximize energy efficiency in site operations ◼ From system design and smart management to equipment upgrades 5 critical systems 25 technology categories 242 projects Steam Generation &
Slide 31: Best Practices
Best Practices
Slide 32: Flagship Green Factory: Dundalk, Ireland
Best Practices WuXi Biologics Flagship Green Factory Dundalk, Ireland Smart building design 2023 ISPE Facility of the Year ISO 50001 energy management 100% Rainwater collection Utilize natural light Award for Operations ISO 14001 environment management Green electricity Water storage 1100+m3 Motion-
Slide 33: Flagship Green Factory: Wuxi, China
Best Practices WuXi Biologics Flagship Green Factory Wuxi, China Advocate green commuting Water-Saving Enterprise and Absolute carbon Energy Management Roof top solar 80% electrical shuttle bus Green Development Leading emission reduction Information System power system 80% e-cars for business Enter
Slide 34: Best Practices: AstraZeneca
Best Practices China UK AstraZeneca 2024 World Economic Forum • AI computer vision • Partnership with CR Gas and Everbright Environment on a biomethane green energy project Lighthouse • End-to-end factory process • Provide Wuxi Site with 36,000 MWh of biomethane and biomethane-based steam annually •
Slide 35: Best Practices: Johnson & Johnson
Best Practices China Belgium Johnson & Johnson J&J’s CO2 Capital Relief Program • Geothermal Plant at J&J Innovative Medicine Campus in Belgium • Provide financial support annually to internal energy-saving projects with carbon • Belgium’s first industrial-scale private geothermal project completed
Slide 36: Best Practices: Novartis and GSK
Best Practices Novartis Institutes for BioMedical Research, Cambridge Campus GSK Singapore Site Novartis GSK Develop science-based carbon Explore renewable energy reduction pathway application Decarbonization targets Systematically integrate life-cycle approved by SBTi, assessment (LCA) in R&D pipel
Slide 37: Closing Remarks
Closing Remarks ﹥ Build environmentally friendly and low-carbon business ﹥ Strengthen product life cycle carbon assessment ﹥ From active commitments to tangible actions across value chain ﹥ Empower partners to go global with sustainable competitive advantages ﹥ Collaborate with clients worldwide for
Slide 38: Reference
Reference 1. https://www.contractpharma.com/addressing-industry-challenges-with-single-use-technologies/ 16. https://www.upphandlingsmyndigheten.se/en/criteria/ 2. "Sustainable biopharmaceutical manufacturing: Reducing carbon footprint through single-use 17. https://peghub.org/lca technologies" (Jou
Slide 39: About WuXi Biologics
About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit